Ballentine Partners, LLC 4 D Molecular Therapeutics, Inc. Transaction History
Ballentine Partners, LLC
- $7.1 Billion
- Q3 2025
A detailed history of Ballentine Partners, LLC transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Ballentine Partners, LLC holds 16,359 shares of FDMT stock, worth $177,495. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,359Holding current value
$177,495% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding FDMT
# of Institutions
137Shares Held
40.5MCall Options Held
70.6KPut Options Held
13.1K-
Black Rock Inc. New York, NY4.9MShares$53.1 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA4.63MShares$50.2 Million2.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.56MShares$49.5 Million0.66% of portfolio
-
Goldman Sachs Group Inc New York, NY4.13MShares$44.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.58MShares$27.9 Million0.0% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $351M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...